Source comparison
MK-677 Dosing Protocols: Comparison
| Protocol | Dose | Frequency | IGF-1 Elevation (Mean) | Bone Marker Response | Side Effect Incidence | Professional Assessment ||—|—|—|—|—|—|| Conservative Baseline | 12.5mg | Once daily (PM) | 47% above baseline | P1NP +19–22%, CTX −12% | Water retention 15%
This comparison does not assign a generated winner or score.
- | Protocol | Dose | Frequency | IGF-1 Elevation (Mean) | Bone Marker Response | Side Effect Incidence | Professional Assessment ||—|—|—|—|—|—|| Conservative Baseline | 12.5mg | Once daily (PM) | 47% above baseline | P1NP +19–22%, CTX −12% | Water retention 15%, glucose stable | Best for initial tolerability assessment or individuals with metabolic concerns. Lower efficacy ceiling || Standard Research Dose | 20mg | Once daily (PM) | 72% above baseline | P1NP +28%, CTX −18%, BMD +2.8% (12 months) | Edema 28%, mild carpal tunnel 12% | Validated in multiple bone density trials. Optimal risk-reward for most research protocols || Upper Validated Range | 25mg | Once daily (PM) | 89% above baseline | P1NP +34%, TBS +6.4%, lean mass +3.1kg (24 weeks) | Insulin resistance 41%, edema 19% | Maximal anabolic signaling but requires glucose and fluid monitoring. Not suitable for pre-diabetic subjects || Pulse Dosing (Experimental) | 12.5mg AM / 12.5mg PM | Twice daily | 68% above baseline | P1NP +24%